Patents Examined by Gabriele E. Bugaisky
  • Patent number: 6264953
    Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: July 24, 2001
    Assignee: Zonagen, Inc.
    Inventor: Bonita Sue Dunbar
  • Patent number: 6265376
    Abstract: Novel plectoxins isolated from the Primitive Hunting Spider, Plectreurys tristis are described, and their amino acid sequences are presented. These are toxic to various groups of insects, including Lepidopterans. A particularly potent plectoxin is Plt-VI. The plectoxins may be cloned into a baculovirus vector and hasten its speed of kill.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: July 24, 2001
    Assignee: Novartis AG
    Inventors: Douglas J. Leisy, Gary B. Quistad, Wayne S. Skinner
  • Patent number: 6248875
    Abstract: A MORT1 gene initially cloned from HeLa cells and identified as a member of the receptor mediated apoptotic pathway, is expressed in the human neuronal cell line, NTERA2. Isolation of the MORT1 from this cell line revealed a transcript isoform that differed from the known MORT1 sequence by a deletion of 21 base pairs (bp 172-192 of the coding sequence). Cloning of MORT1 from adult human brain revealed two isoforms, one similarly deleted for bp 172-192, the other with a basepair substitution, A for G at position 173. Assessment of MORT1 function in a yeast two hybrid system indicates that the deleted and intact forms of MORT1 differ in their capacity to interact with other members of the apoptotic pathway.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: June 19, 2001
    Assignee: American Home Products Corporation
    Inventors: Andrew T. Wood, Brendan William Bingham, Kathleen H. Young, Camelia Birsan
  • Patent number: 6248543
    Abstract: A method for screening compounds for antimicrobial activity is described that utilizes bacterial protein-protein binding in vitro. The method may be performed using immobilized elements and the immobilization may be carried out using a variety of immobilization means (e.g., columns, beads, adsorbents, nitrocellulose paper, etc.) in order to screen large libraries of compounds.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: June 19, 2001
    Assignee: Case Western Reserve University
    Inventors: Piet A. J. de Boer, Cynthia A. Hale
  • Patent number: 6242569
    Abstract: The invention provides methods and compositions relating to apopotosis regulating proteins, known as Casper proteins, and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed Casper encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed Casper gene, Casper-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: June 5, 2001
    Assignee: Tularik, Inc.
    Inventors: Hong-Bing Shu, David V. Goeddel
  • Patent number: 6235283
    Abstract: This invention relates to an antigen isolated from the cattle tick Boophilus microplus and to the gene coding for that antigen and to the protein product of that gene. The antigen when used in part or in entirety as an immunogen administered to cattle as a vaccine results in the production by the cattle of an immune response which is capable of damaging ticks feeding on vaccinated cattle to such an extent that the survival of such ticks is decreased and/or the reproductive capacity of the ticks is decreased to such an extent that the antigen coded for by the gene can be used as an effective vaccine against said ticks.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 22, 2001
    Assignees: Biotechnology Australia Pty. Ltd., Commonwealth Scienticfic and Industrial Research Organization
    Inventors: Gary Stewart Cobon, Joanna Terry Moore, Law Anthony Yorke Johnston, Peter Willadsen, David Harold Kemp, Alagacone Sriskantha, George Alfred Riding, Keith Norman Rand
  • Patent number: 6228620
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an &agr;1-antitrypsin signal sequence.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 8, 2001
    Assignees: Chiron Corporation, Novo Nordisk A/S
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
  • Patent number: 6210890
    Abstract: The invention provides a human peroxisomal thioesterase (PxTE) and polynucleotides which identify and encode PxTE. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PxTE.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: April 3, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley
  • Patent number: 6211148
    Abstract: The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: April 3, 2001
    Assignee: The Regents of the University of California
    Inventors: Michael E. Selsted, James S. Cullor
  • Patent number: 6204246
    Abstract: The present invention provides, inter alia, a B.t. hybrid toxin fragment comprising at its C-terminus domain III of a first Cry protein, or a part of said domain or a protein substantially similar to said domain; and comprising at its N-terminus the N-terminal region of a second Cry protein, or a part of said region or a protein substantially similar to said region.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: March 20, 2001
    Assignee: Novartis AG
    Inventors: Hendrik Jan Bosch, Willem Johannes Stiekema
  • Patent number: 6174721
    Abstract: Chimeric proteins possessing Kunitz-type domain 1 of TFPI-2 and Kunitz-type domain 2 of TFPI are disclosed, as are muteins of TFPI and TFPI-2. Nucleic acid sequences, expression vectors and transformed host cells encoding and capable of producing the disclosed chimeric proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the chimeric proteins and muteins are disclosed.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: January 16, 2001
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Abla A. Creasey
  • Patent number: 6171827
    Abstract: There is disclosed molecules comprising at least a first moiety having the activity of a procollagen C-propeptide and a second moiety selected from any one of the group of an alien collagen &agr;-chain and non-collagen materials, the first moiety being attached to the second moiety. Also disclosed are collagen molecules, fibrils and fibres comprising a non-natural combination of collagen &agr;-chains, DNA encoding same, expression hosts transformed or transfected with same, transgenic animals and methods of producing a non-natural collagen.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: January 9, 2001
    Assignee: The Victoria University of Manchester
    Inventors: Neil Bulleid, Karl Kadler
  • Patent number: 6168928
    Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.
    Type: Grant
    Filed: May 21, 1998
    Date of Patent: January 2, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
  • Patent number: 6162430
    Abstract: A method is provided that accelerates the rate of kill of pests such as from the order Lepidoptera. The method comprises treating the pests or their loci with at least two different insect toxins which are expressed from at least one recombinant microbe. Pairs of toxins that do not compete with each other on the same binding site and that differ in their pharmacology have been found to provide synergistic control. Preferred insecticidal microbes are baculoviruses.
    Type: Grant
    Filed: February 6, 1998
    Date of Patent: December 19, 2000
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Rafael Herrmann, Haim Moskowitz
  • Patent number: 6160091
    Abstract: Novel Myc-binding zinc finger proteins, their preparation and their use are provided.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: December 12, 2000
    Assignee: Prolifix Limited
    Inventors: Karen Peukert, Frank Haenel, Martin Eilers
  • Patent number: 6150139
    Abstract: A bacteriocin having activity against bacteria including Listeria monocytogenes is obtained by culturing cells of a strain of Micrococcus varians, particularly cells of deposited strains CNCM I-1586 and CNCM I-1587, to obtain cultured cells and a supernatant and by separating the supernatant from the cultured cells to obtain the supernatant which contains the bacteriocin which, in turn, may be isolated from the supernatant.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: November 21, 2000
    Assignee: Nestec S.A.
    Inventors: Beat Mollet, John Peel, David Pridmore, Nadji Rekhif, Suri Bruno
  • Patent number: 6150150
    Abstract: Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode a unique subtype of the low K.sub.m, cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IV.sub.B mRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an .about.4-kb mRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional .about.5-kb hPDE IV.sub.B.sup.- related mRNA species was detected in brain tissue. Expression of hPDE IV.sub.B in a genetically-engineered PDE-deficient strain of the yeast Saccharomyces cerevisiae resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: 1) low K.sub.m (4.3 .mu.M) for cAMP, 2) high K.sub.m (>3 mM) for cGMP, and 3) sensitivity to rolipram (K.sub.i =0.085 .mu.M), a selective inhibitor of PDE IV. Recombinant hPDE IV.sub.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: November 21, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: George P. Livi, Megan M. McLaughlin, Theodore J. Torphy
  • Patent number: 6114146
    Abstract: The invention describes an expression plasmid containing a dicistronic transcription/translation unit, which unit comprises a sequence for a foreign protein and a sequence for a fusion protein, the fusion protein containing at least one selection marker and at least one amplification marker. Further described is a method of producing foreign proteins by using the plasmids according to the invention, as well as cell lines transformed with the plasmid according to the invention.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: September 5, 2000
    Assignee: Baxter Aktiengesellschaft
    Inventors: Sabine E. Herlitschka, Uwe Schlokat, Falko-Guenter Falkner, Friedrich Dorner
  • Patent number: 6114504
    Abstract: Methods of reducing cystine containing animal and plant proteins, and improving dough and baked goods' characteristics is provided which includes the steps of mixing dough ingredients with a thiol redox protein to form a dough and baking the dough to form a baked good. The method of the present invention preferably uses reduced thioredoxin with wheat flour which imparts a stronger dough and higher loaf volumes. Methods for reducing snake, bee and scorpion toxin proteins with a thiol redox (SH) agent and thereby inactivating the protein or detoxifying the protein in an individual are also provided. Protease inhibitors, including the Kunitz and Bowman-Birk trypsin inhibitors of soybean, were also reduced by the NADP/thioredoxin system (NADPH, thioredoxin, and NADP-thioredoxin reductase) from either E. coli or wheat germ. When reduced by thioredoxin, the Kunitz and Bowman-Birk soybean trypsin inhibitors lose their ability to inhibit trypsin.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 5, 2000
    Assignee: The Regents of the University of California
    Inventors: Bob B. Buchanan, Karoly Kobrehel, Boihon C. Yee, Joshua H. Wong, Rosa Lozano, Jin-an Jiao, Sungho Shin
  • Patent number: 6113951
    Abstract: Methods of reducing cystine containing animal and plant proteins, and improving dough and baked goods' characteristics is provided which includes the steps of mixing dough ingredients with a thiol redox protein to form a dough and baking the dough to form a baked good. The method of the present invention preferably uses reduced thioredoxin with wheat flour which imparts a stronger dough and higher loaf volumes. Methods for reducing snake, bee and scorpion toxin proteins with a thiol redox (SH) agent and thereby inactivating the protein or detoxifying the protein in an individual are also provided. Protease inhibitors, including the Kunitz and Bowman-Birk trypsin inhibitors of soybean, were also reduced by the NADP/thioredoxin system (NADPH, thioredoxin, and NADP-thioredoxin reductase). When reduced by thioredoxin, the Kunitz and Bowman-Birk soybean trypsin inhibitors lose their ability to inhibit trypsin.
    Type: Grant
    Filed: November 21, 1994
    Date of Patent: September 5, 2000
    Assignee: The Regents of the University of California
    Inventors: Bob B. Buchanan, Karoly Kobrehel, Boihon C. Yee, Joshua H. Wong, Rosa Lozano, Jin-an Jiao, Sungho Shin